Heart drug trial halted after only 6 patients

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Males and females ≥ 18 to 85 years of age. 2. Diagnosed with NSTEMI. 3. Patients who will undergo PCI during the index hospitalization for an NSTEMI. 4. Ability to understand and willing to give written informed consent. 5. Women of childbearing potential must have a negative pregnancy test or be post-menopausal for at least 1 year before enrollment or be permanently sterilized since ≥6 weeks. Females of childbearing potential and males with partners of childbearing potential must be using effective contraception. Exclusion Criteria: 1. .Cardiogenic shock or prolonged cardiopulmonary resuscitation (CPR). 2. Active bleeding, bleeding diathesis, coagulopathy. 3. Any history of intracranial bleeding or structural abnormalities. 4. Prior transient ischemic attack, prior stroke within 6 months. 5. Index MI is STEMI or new left bundle branch block. 6. The following planned procedures within 30 days after enrollment: staged PCI, CABG, valve surgery, or additional invasive procedures. 7. Pre-existing atrial fibrillation or prolonged QTcF (470ms in men, 480ms in women). 8. Anticipated requirement for oral anticoagulants before Day 30. 9. CRUSADE bleeding risk score \>40. 10. Suspected aortic dissection. 11. History of gastrointestinal or genitourinary bleeding within the previous 3 months. 12. Refusal to receive blood transfusion if needed during the study. 13. Major surgery in the last month. 14. History of heparin-induced thrombocytopenia and bleeding diathesis. 15. Severe uncontrolled hypertension. 16. Prior (within 30 days prior to enrollment) or planned administration of thrombolytics, glycoprotein IIb/IIIa inhibitors, bivalirudin, or fondaparinux for the index MI. 17. Known relevant hematological deviations: hemoglobin (male) \< 11 g/dL, hemoglobin (female) \< 10 g/dL, hematocrit \< 35%, platelet count \< 100,000 cells/µL. 18. Use of Coumadin derivatives and/or Factor Xa inhibitor drugs within the last 7 days. 19. Chronic therapy with non-steroidal anti-inflammatory drugs (NSAIDs; except aspirin) , cyclooxygenase (COX)-2 inhibitors within 1 month before screening. 20. Known malignancies or other comorbid conditions with life expectancy \< 1 year. 21. Known severe liver disease (i.e., aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\] \> 3 × ULN). 22. Known positive serology for hepatitis B \& C, HIV screen. 23. Known chronic kidney disease with estimated glomerular filtration rate (eGFR) \<30 mL/min and/or dialysis. 24. Known allergy or intolerance to aspirin, clopidogrel, ticagrelor, prasugrel, bivalirudin, unfractionated heparin, P2Y12 antagonists, or contrast.